Arrowhead制药 ARWR 深 沪
等待开盘 10-18 09:30:00 美东时间
20.84
-0.260
-1.23%
华盛通- 最 高21.44
- 今 开21.10
- 成交量 165.82万股
- 最 低 20.65
- 昨 收 21.10
- 总市值 25.84亿
- 52周最高 39.83
- 市盈率 静 --
- 换手率 1.34%
- 52周最低 17.05
- 委 比 -38.20%
- 总股本 1.24亿
- 历史最高 93.66
- 量 比 1.42
- 振 幅 3.74%
- 历史最低 1.22
- 每 手 1
- 风险率 4.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Maintaining Hold on Arrowhead Pharmaceuticals Amid Promising CNS Portfolio Developments
In a report released today, Michael Ulz from Morgan Stanley maintained a Hold r...
10-08 18:18
Stocks with three weeks of deteriorating technicals by Piper Sandler
Piper Sandler analysts put out a list of companies that show three weeks of deteriorating technical grade rankings within their universe of coverage. Within energy (XLE): Core Laboratories Inc. (CLB) ...
08-20 23:27
Arrowhead Pharmaceuticals’ Breakthrough Obesity Treatments Propel Buy Rating
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Arrowhead P...
08-16 01:25
Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), Arrowhead Pharmaceuticals (ARWR) and Nuvalent (NUVL)
Analysts have been eager to weigh in on the Healthcare sector with new ratings ...
08-13 23:40
快讯 | 摩根士丹利将目标价从27.00美元提高至29.00美元，适用于箭头制药公司。
Arrowhead Pharmaceuticals Inc : Morgan Stanley Raises Target Price to $29.00 Fr...
08-09 21:17
Arrowhead Pharmaceuticals Announces $500M Strategic Financing Facility
- Balance sheet strengthened with long-term, non-dilutive capital- $400 million funded at close with the potential to draw an additional $100 million- Immediately enhances Arrowhead's ability to advance plozasiran
08-09 05:03
Arrowhead Pharmaceuticals announces $500M strategic financing facility with Sixth Street
Arrowhead Pharmaceuticals (NASDAQ:ARWR) on Thursday said it has entered into a strategic financing agreement with Sixth Street for significant, long-term, non-dilutive capital to fund innovation and g...
08-09 04:24
Arrowhead Pharma Q3 2024 GAAP EPS $(1.38) Misses $(0.53) Estimate
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(0.53) by 160.38 percent.
08-09 04:08
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. W...
07-16 19:36
BMO sees BMRN, LEGN, SLN as attractive M&A targets
BMO Capital Markets said it views BioMarin Pharmaceutical (NASDAQ:BMRN), Legend Biotech (NASDAQ:LEGN) and Silence Therapeutics (NASDAQ:SLN) as attractive takeover targets following Eli Lilly’s (LLY) a...
07-10 03:00
